Clindamycin hydrochloride

The main ingredient of this product is clindamycin hydrochloride, and its chemical name is 6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-7(S)-chloro-6,7,8-trideoxy-L-threo-α-D-galactoctinopyranoside hydrochloride.

1. This product can enhance the neuromuscular blockade of inhaled anesthetics, leading to skeletal muscle weakness and respiratory depression or paralysis (apnea). Caution should be taken when using it during or after surgery. Treatment with anticholinesterase drugs or calcium salts is expected to be effective. 2. This product can cause pseudomembranous colitis with severe watery diarrhea during or even a few weeks after the course of treatment when used in combination with antiperistaltic antidiarrheal drugs and antidiarrheal drugs containing white clay. Because it can delay the excretion of colonic endotoxins, thereby causing prolonged and aggravated diarrhea, this product should not be used in combination with antiperistaltic antidiarrheal drugs. When used in combination with antidiarrheal drugs containing white clay, the absorption of this product will be significantly reduced, so the two should not be taken at the same time, and a certain interval (at least 2 hours) is required. 3. This product has a neuromuscular blocking effect and can enhance the effect of neuromuscular blocking drugs. The two should be avoided in combination. When this product is used in combination with anti-myasthenic drugs, the latter will weaken the effect on skeletal muscles. In order to control the symptoms of myasthenia gravis, the dose of anti-myasthenic drugs should be adjusted when used in combination. 4. Chloramphenicol or erythromycin can replace this product at the target site, or inhibit the binding of this product to the bacterial ribosome 50S subunit. In vitro tests show that this product has an antagonistic effect with erythromycin, so this product should not be used in combination with chloramphenicol or erythromycin. 5. When used in combination with opioid analgesics, the respiratory depression of this product and the central respiratory depression of opioids may add up to prolong respiratory depression or cause respiratory paralysis (apnea), so patients must be closely observed or monitored. 6. This product should not be added to infusions with complex components to avoid incompatibility.

The main ingredient of this product is clindamycin hydrochloride.

1. It can enhance the neuromuscular blockade of inhaled anesthetics, leading to skeletal muscle weakness and respiratory depression or paralysis (apnea). Caution should be taken when using it together during or after surgery. Treatment with anticholinesterase drugs or calcium salts is expected to be effective. 2. Used together with antiperistaltic antidiarrheal drugs and antidiarrheal drugs containing white clay: Clindamycin may cause pseudomembranous colitis with severe watery diarrhea during the course of treatment or even a few weeks after the course of treatment. Because it can delay the excretion of colonic endotoxins, thereby causing prolonged and aggravated diarrhea, antiperistaltic antidiarrheal drugs should not be used together. When antidiarrheal drugs containing white clay and clindamycin are taken orally at the same time, the absorption of the latter will be significantly reduced. Therefore, the two should not be taken at the same time and a certain time interval (at least 2 hours) must be maintained. 3. This product has a neuromuscular blocking effect. When used together with anti-myasthenic drugs, the effect of the latter on skeletal muscles will be weakened. In order to control the symptoms of myasthenia gravis, the dose of anti-myasthenic drugs should be adjusted during the combined treatment. 4. Chloramphenicol or erythromycin can replace this product at the target site, or inhibit the latter from binding to the bacterial ribosome 50S subunit. In vitro tests show that this product has an antagonistic effect with erythromycin, so this product should not be used in combination with chloramphenicol or erythromycin. 5. When used in combination with opioid analgesics, the respiratory depression of this product and the central respiratory depression of opioids may lead to prolonged respiratory depression or respiratory paralysis (apnea) due to the cumulative phenomenon, so the patient must be closely observed or monitored. 6. This product can enhance the effect of neuromuscular blocking drugs, and the two should be avoided in combination.

The main ingredient of this product is clindamycin hydrochloride.

1. It can enhance the neuromuscular blockade of inhaled anesthetics, leading to skeletal muscle weakness and respiratory depression or paralysis (apnea). Caution should be taken when using it together during or after surgery. Treatment with anticholinesterase drugs or calcium salts is expected to be effective. 2. Used together with antiperistaltic antidiarrheal drugs and antidiarrheal drugs containing white clay: Clindamycin may cause pseudomembranous colitis with severe watery diarrhea during the course of treatment or even a few weeks after the course of treatment. Because it can delay the excretion of colonic endotoxins, thereby causing prolonged and aggravated diarrhea, antiperistaltic antidiarrheal drugs should not be used together. When antidiarrheal drugs containing white clay and clindamycin are taken orally at the same time, the absorption of the latter will be significantly reduced. Therefore, the two should not be taken at the same time and a certain time interval (at least 2 hours) must be maintained. 3. This product has a neuromuscular blocking effect. When used together with anti-myasthenic drugs, the effect of the latter on skeletal muscles will be weakened. In order to control the symptoms of myasthenia gravis, the dose of anti-myasthenic drugs should be adjusted during the combined treatment. 4. Chloramphenicol or erythromycin can replace this product at the target site, or inhibit the latter from binding to the bacterial ribosome 50S subunit. In vitro tests show that this product has an antagonistic effect with erythromycin, so this product should not be used in combination with chloramphenicol or erythromycin. 5. When used in combination with opioid analgesics, the respiratory depression of this product and the central respiratory depression of opioids may lead to prolonged respiratory depression or respiratory paralysis (apnea) due to the cumulative phenomenon, so the patient must be closely observed or monitored. 6. This product can enhance the effect of neuromuscular blocking drugs, and the two should be avoided in combination.